• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » U.K. industry paid $456.7M in 2014 to underwrite medicines bill

U.K. industry paid $456.7M in 2014 to underwrite medicines bill

March 13, 2015
CenterWatch Staff

The Association of the British Pharmaceutical Industry (ABPI) and the U.K. Department of Health have announced a fourth quarter payment from industry of $119.3 million to underwrite the growth of the medicines bill under the 2014 Pharmaceutical Price Regulation Scheme (PPRS). This takes the total payment made by industry during 2014 to $456.7 million.

In 2014, the growth for the full year was 5.2%—less than the quarter three growth of 5.93%. While this represents growth above the original joint forecast of 3.87%, when compared to the same quarter in 2013 it indicates growth of 3.2%. Increased use of branded medicines is encouraging, but industry still would like to see equal access for patients to all medicines across care sectors.

Alison Clough, ABPI’s executive director commercial, said, “The PPRS provides government and the NHS with a unique opportunity to offer patients access to newer, more innovative medicines at minimal additional cost and today’s announcement demonstrates industry’s commitment to supporting the NHS in a time of austerity. However there is significant disparity of growth across the primary and secondary care settings as well as between different therapy areas. We are committed to working with all parties to ensure that the barriers to the use of new medicines in all care settings are removed and that NICE appropriately assesses medicines so that ring-fenced funds for selected therapy areas are not needed.”

“Industry agreed to the PPRS in order to improve the use of innovative medicines in the U.K.,” said Clough. “We are working with the Department of Health, NHS England and government to ensure action in key areas such as changes to NICE’s decision making framework and medicines optimization to maximize the benefits of the PPRS so that patients can get the right medicine at the right time.”

Industry will underwrite any further expenditure by the NHS subject to specific exceptions set out in chapter 6 of the PPRS. The pharmaceutical industry has agreed to keep NHS expenditure on branded medicines flat for two years and under 2% growth for the following three year. Companies will make percentage payments based on any difference between allowed growth and actual growth in NHS expenditure on branded medicines, subject to the agreed exclusions.

One hundred and thirty-four companies, representing 93% of the U.K. branded industry, joined the voluntary PPRS, which was agreed in November 2013 following the most complex pricing negotiations ever experienced.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing